

Registration number: 03574227

Gen-Pharma (UK) Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 31 March 2016

FRIDAY



A5KZKUFV

A17

02/12/2016

#76

COMPANIES HOUSE

Gen-Pharma (UK) Limited

Company Information

Directors	Mr E C Bessant Ms A Z D'Abreo
Company secretary	Ceuta Secretaries Limited
Registered office	Hill House 41 Richmond Hill Bournemouth Dorset BH2 6HS

Gen-Pharma (UK) Limited

Directors' Report for the Year Ended 31 March 2016

The Directors present their report and the financial statements for the year ended 31 March 2016.

Directors of the Company

The directors who held office during the year were as follows:

Mr E C Bessant

Ms A Z D'Abreo

Ms M Y Sherry (resigned 4 June 2015)

Principal activity

The principal activity of the company is that of a dormant company.

Small companies provision statement

This report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

Approved by the Board on 22 August 2016 and signed on its behalf by:



.....
Mr E C Bessant
Director

Gen-Pharma (UK) Limited

(Registration number: 03574227)
Balance Sheet as at 31 March 2016

	Note	2016 £	2015 £
Creditors: Amounts falling due within one year	3	<u>(2,811)</u>	<u>(2,811)</u>
Capital and reserves			
Called up share capital		1	1
Profit and loss account		<u>(2,812)</u>	<u>(2,812)</u>
Total equity		<u>(2,811)</u>	<u>(2,811)</u>


For the financial year ending 31 March 2016 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

Approved and authorised by the Board on 22 August 2016 and signed on its behalf by:



.....
Mr E C Bessant
Director

Gen-Pharma (UK) Limited

Notes to the Financial Statements for the Year Ended 31 March 2016

1 General information

The company is a private company limited by share capital incorporated in England and Wales.

The address of its registered office is:

Hill House
41 Richmond Hill
Bournemouth
Dorset
BH2 6HS
England

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Financial instruments

Basic financial instruments are recognised at amortised cost, except for investments in non-convertible preference and non-puttable ordinary shares which are measured at fair value, with changes recognised in profit or loss. Derivative financial instruments are initially recorded at cost and thereafter at fair value with changes recognised in profit or loss.

3 Creditors

	2016 £	2015 £
Due within one year		
Amounts due to related parties	<u>2,811</u>	<u>2,811</u>

The amount due to group undertakings is interest free, unsecured and is repayable on demand.

Gen-Pharma (UK) Limited

Notes to the Financial Statements for the Year Ended 31 March 2016

4 Share capital

Allotted, called up and fully paid shares

	2016		2015	
	No.	£	No.	£
Ordinary share of £1 each	<u>1</u>	<u>1</u>	<u>1</u>	<u>1</u>

5 Related party transactions

The company has taken advantage of the exemptions available from FRS 102 Section 1A not to disclose transactions with other group undertakings.

6 Parent and ultimate parent undertaking

In the opinion of the directors, there is no single controlling party.

The company's immediate parent is Ceuta Healthcare Limited, incorporated in England and Wales.

The ultimate parent is Ceuta Holdings Limited, incorporated in England and Wales.

The largest and smallest group in which the results of the company are consolidated, which is that headed by Ceuta Holdings Limited. The consolidated accounts of this company are available to the public and may be obtained from Hill House, 41 Richmond Hill, Bournemouth, Dorset, BH2 6HS. No other group accounts include the results of the company.